期刊文献+

^(99)Tc^m-抗人膀胱癌-人鼠嵌合抗体在荷人膀胱癌裸鼠的放射免疫显像 被引量:4

Labeling of anti-human bladder tumor chimeric antibody with^(99)Tc^m and radioimmunoimaging of bladder carcinoma xenograft in nude mice
下载PDF
导出
摘要 目的 研究99Tcm 抗人膀胱癌人 鼠嵌合抗体ch BDI对膀胱癌细胞的体外结合性能、在荷人膀胱癌裸鼠中的体内分布及对肿瘤的靶向定位性能。方法 用改进的Schwarz方法进行99Tcm 标记 ,经SephadexG 5 0柱分离纯化。用纸层析法测定标记率与放化纯 ;用Lindmo的方法测定免疫活性分数 ;用Scatchard作图法求得亲和常数。荷人膀胱癌裸鼠静脉注射99Tcm ch BDI 11.1MBq(30 μg) ,分别于 2、6、2 0及 2 4h行放射免疫显像。用感兴趣区 (ROI)技术获得全身和肿瘤放射性计数及肿瘤与对侧正常组织 (T NT)的放射性比值。 2 4h显像后处死裸鼠 ,测定体内放射性分布 ,计算每克组织百分注射剂量率 (%ID g)及T NT比值。结果 99Tcm ch BDI标记率为 (6 6 .5± 7.3) % ,放化纯 >90 % ,免疫活性分数为 76 % ,亲和常数为 3.5 6× 10 9L mol。荷人膀胱癌裸鼠放射免疫显像结果示 ,静脉注射后 6h肿瘤显影清晰 ,随时间延长更清晰。全身放射性计数随时间延长迅速降低 ,肿瘤放射性计数下降缓慢 ,T NT比值随时间增高。荷瘤裸鼠体内分布结果示 ,静脉注射后 2 4h肿瘤 %ID g为 17.4 ,除肾脏外 ,肿瘤与其他正常组织有很高的T NT比值 ,与脑、肌肉、小肠壁、骨骼及心壁的T NT比值分别为 136 .0、5 5 .1、39.3、2 9.7及 2 7 9。结论 ch BDI具有良? Objective To study the in vitro immunoreactivity and in vivo tissue distribution, tumor targeting property of anti-human bladder tumor human-murine chimeric antibody (ch-BDI) labeled with 99Tcm and to investigate its possibility for being used in guiding diagnosis and guiding therapy of bladder cancer. Methods The ch-BDI was labeled with 99Tcm by improved Schwarz method and the labeled antibody was purified by Sephadex G-50. Labeling yield and radiochemical purity were measured by paper chromatography. The immunoreactive fraction and association constant (K a) were measured by Lindmo method and Scatchard analysis, respectively. 11.1 MBq(30 μg) 99Tcm-ch-BDI was intravenously injected into nude mice bearing human bladder cancer xenografts in the right thigh and radioimmunoimaging (RII) was performed 2, 6, 20 and 24 h postinjection. The images were processed by region of interest (ROI) method to acquire the counts of whole body and the tumor and the counts ratios of tumor to contralateral normal tissue or to tissues of other non-tumor bearing organs. The mice were killed after 24 h postinjection imaging and tissue distribution was measured. %ID/g and target to nontarget (T/NT) ratios were calculated. Results The labeling yield and radiochemical purity of 99Tcm-ch-BDI were (66.5±7.3)% and >90%,respectively. The immunoreactive fraction was 76% and K a was 3.56×109 L/mol. RII showed that the tumor was clearly visualized 6 h postinjection and becoming clearer along with time prolonging. The radioactivity of whole body decreased rapidly with time, whereas the radioactivity of the tumor decreased slowly. The T/NT ratios was increased with time. Biodistribution results showed that tumor uptake was 17.4 %ID/g 24 h postinjection. T/NT ratios were very high except for the kidney. T/NT ratios for brain, muscle, intestinal wall, bone and heart wall were 136.0, 55.1, 39.3, 29.7 and 27.9, respectively. Conclusion 99Tcm-ch-BDI exhibits excellent immunoreactivity and tumor targeting property and has potential applications in guiding diagnosis and guiding therapy of bladder cancer.
出处 《中华核医学杂志》 CAS CSCD 北大核心 2003年第4期212-214,共3页 Chinese Journal of Nuclear Medicine
关键词 膀胱癌 ^99TC^M 药代动力学 抗人膀胱癌人-鼠嵌合抗体 ch-BDI 诊断 治疗 Bladder neoplasms Animal, laboratory Mice, nude Antibodies, monoclonal Pharmacokinetics
  • 相关文献

参考文献7

二级参考文献10

  • 1俞莉章,中华泌尿外科杂志,1993年,14卷,252页
  • 2俞莉章,中华泌尿外科杂志,1991年,12卷,83页
  • 3Lee Y S,Cancer Res,1988年,48卷,559页
  • 4俞莉章,Scanand J Urol Nephorl,1994年,157卷,Suppl期,13页
  • 5马爱红,中华泌尿外科杂志,1990年,11卷,195页
  • 6周丽君,中国免疫学杂志,2000年,16卷,9期,51页
  • 7Yu L Z,Chin Med J,1998年,111卷,404页
  • 8Yu L Z,Urol Res,1996年,24卷,273页
  • 9李竞,王卓智,王琰,刘群英,化冰,陈宇萍,朱迎春,董志伟.抗人胃癌3H11人-鼠嵌合抗体的构建及表达[J].中国肿瘤生物治疗杂志,1998,5(2):116-120. 被引量:5
  • 10周丽君,陈晓穗,王欲晓,朱迎春,张海荣,谢帮铁,王琰.抗TNF-α人-鼠嵌合抗体的构建及表达[J].中国免疫学杂志,2000,16(9):491-494. 被引量:2

共引文献15

同被引文献99

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部